Alleviate Health is a technology company.
Alleviate Health has raised $4.0M across 1 funding round.
Alleviate Health has raised $4.0M in total across 1 funding round.
Alleviate Health is an AI-driven platform that accelerates patient recruitment for clinical research sites by deploying human-in-the-loop AI agents. These agents engage potential patients via SMS and voice 24/7, verify eligibility against trial protocols, schedule visits, and integrate data into a specialized CRM to optimize recruitment funnels[1][2][3]. Serving clinical trial sites across the US and Canada, it addresses the bottleneck of manual outreach that delays trials, burns out staff, and slows medical advancements—already operational at 190+ sites, supporting 500k+ patient interactions across 300+ trials, with partnerships including seven of the top 15 US site networks like Alcanza and CenExel[1][2][3]. Backed by a $4.3M seed round led by Andreessen Horowitz in October 2025, the company demonstrates strong early growth momentum from stealth operations to live deployment[1][2][3].
Alleviate Health emerged from the recognition of inefficiencies in clinical trial recruitment, where sites handle thousands of patient leads manually across fragmented systems. Founded in Durham, North Carolina, the company operated in stealth for a year, achieving early traction with 500k+ patient interactions before publicly launching in October 2025 alongside its $4.3M seed funding led by Andreessen Horowitz[1][2][3]. Specific founders are not detailed in available sources, but the pivotal moment was proving impact at scale—such as enabling hundreds of screening appointments across the Alcanza network, as noted by CEO Carlos Orantes[1][3]. This validated the human-in-the-loop AI model, transitioning from pilot to partnerships with major site networks like CenExel, M3 Wake, Centricity, and Eximia[3].
Alleviate Health rides the AI-for-healthcare wave, specifically targeting clinical trials—a $50B+ market where recruitment delays account for 80% of trial timelines and up to 30% of costs. Timing aligns with surging AI adoption in biotech post-2023 LLM breakthroughs, enabling natural language processing for protocol matching and patient comms[1][3]. Favorable forces include regulatory pushes for faster trials (e.g., FDA initiatives), site network consolidation, and investor interest from firms like a16z betting on AI to compress drug development cycles. By empowering sites—the "backbone" of trials—Alleviate influences the ecosystem, potentially accelerating therapies for unmet needs while improving patient experiences[1][2].
With seed funding secured and product live at scale, Alleviate Health is poised for rapid expansion—targeting more site networks, international growth, and deeper AI enhancements like predictive eligibility matching. Trends like multimodal AI (voice/SMS integration) and personalized medicine will amplify its edge, while partnerships could drive network effects in a consolidating trials market. Its influence may evolve from recruitment accelerator to full trial operations platform, shortening paths to market for breakthrough therapies and solidifying a16z's bio-AI portfolio. This positions Alleviate as a linchpin in making clinical research faster and more human-centered, directly tackling the core bottleneck affirmed at launch[1][3].
Alleviate Health has raised $4.0M in total across 1 funding round.
Alleviate Health's investors include Alt Capital, Andreessen Horowitz, Y Combinator.
Alleviate Health has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $4.0M Seed | Alt Capital, Andreessen Horowitz, Y Combinator |